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Abstract
Background: C-reactive protein (CRP) is an early marker for inflammation, and a relationship between serum CRP
levels and survival in oral cancer has been demonstrated previously. In this study, we investigated the roles of CRP
in different oral cancer subsites.
Methods: Three hundred and forty-three oral squamous cell carcinoma patients between June 1999 and March
2015 were retrospectively reviewed. Serum CRP levels were measured preoperatively.
Results: The elevation of CRP levels (≥5.0 mg/L) was significantly correlated with pathologic tumor status, pathologic
nodal status, nodal extracapsular spread, tumor stage, skin invasion, tumor depth (≥10 mm), and bone invasion.
The correlation between elevation of CRP and clinicopathologic factors was more evident in the buccal cancer
compared to other tumor subsites. The disease-free survival and overall survival correlation was significant in buccal cancer
(p = 0.003 and p < 0.001) but not in tongue cancer (p = 0.119 and p = 0.341) or other oral cancer subsites
(p = 0.246 and p = 0.696).
Conclusions: Preoperative serum CRP level was a prognosticator in oral squamous cell carcinoma, and its effect was
more prominent in buccal cancer that occurs more frequently in areca-quid (AQ) endemic regions.
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Background
Oral cavity cancer is a malignancy with increased inci-
dence in recent years. As it is widely known, alcohol,
betel nut, and cigarette consumption increased the
risks of oral cavity cancer [1, 2]. Chronic exposure to
these carcinogenic factors can cause transform the oral
cavity mucosa into malignancy. Part of the Taiwanese popu-
lation commonly consumes cigarettes and betel nuts; it
makes the oral cancer fifth in the top ten common cancers
in Taiwan, and its incidence still increases in recent
years [3]. For oral cancer treatments, a decision of
surgical intervention, radiotherapy, chemotherapy, or
combination, depends on cancer staging, lymph node
metastasis, pathologic factors, and distant metastasis.
In recent years, more and more research studies
proved that in addition to preoperative cancer staging,
the patients’ preoperative condition plays an important
role in predicting the prognosis of oral cavity cancer. In-
flammation, which may contribute to the formation of
oral cavity cancer or was resulted from the host reaction
to the tumor progression (Fig. 1), was also found to
correlate with patient’s prognosis [4]. Some inflammatory
markers such as interleukin-6, tumor necrotic factor, and
C-reactive protein (CRP) were recently identified as prog-
nostic markers in oral cavity cancer [4–7]. CRP is an acute
phase protein, which is synthesized by the liver and
released into the bloodstream within several hours after
tissue injury, being able to reflect infection or an inflam-
matory status [8]. In many human cancers, CRP has a role
as a prognostic predicting factor [5, 7, 9–11].
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We previously demonstrated that CRP was an inde-
pendent prognostic factor in oral cavity squamous cell
carcinoma (OSCC) [7]. However, the studies were
limited by the case number and follow-up period. In this
study, we expanded our patient number and included a
longer follow-up period to clarify the prognostic role in
OSCC. Also, we stratified our patients according to dif-
ferent tumor subsites. We hope that the analysis in this




Three hundred and forty-three patients between June
1999 and March 2015 in Chang Gung Memorial Hospital
were retrospectively recruited. The inclusion criteria were
primary OSCC without previous treatment before. The
exclusion criteria were patients with verrucous carcinoma
or distant metastasis. All patients included in this study
received radical surgery in curative intent and with or
without adjuvant chemo-radiation therapy. After treat-
ments, all the patients were followed up regularly in the
clinic and ended on September 2015 or on the date that
the patients expired.
OSCC staging and treatment
The patients in this series underwent an extensive pre-
operative survey, which included a detailed medical history
and a complete physical examination, complete blood
count, routine blood biochemistry, chest radiographs, com-
puted tomography or magnetic resonance imaging scans of
the head and neck, bone scan or positron emission tomog-
raphy (PET), and liver ultrasound. The tumor staging
followed the guidelines of the American Joint Committee
on Cancer (7th edition) [12]. The tumor excisions in all
patients were done by ≥1 cm safety margin. The tumor in-
vasiveness parameters, which included tumor size, tumor
cell differentiation, lymph node metastasis, lymph node
extracapsular spread (ECS), depth of tumor invasion, peri-
neural invasion, and soft tissue and lymphovascular inva-
sion, were documented in the pathology report. For
patients with advanced tumor stage (T3 or T4), lymph
node ECS, tumor depth ≥10 mm, or poor differentiation,
postoperative radiotherapy or concomitant chemoradio-
therapy would be suggested [13].
Measurement of CRP
The serum CRP level was measured preoperatively at the
time of tissue diagnosis. It was measured before any med-
ical treatment was delivered, including antibiotics [6, 13].
The levels of CRPs were measured by an auto-analyzer
(Hitachi Medico, Tokyo, Japan). Elevation of serum CRP
level was defined at a cut point of ≥5.0 mg/L.
Statistical analysis
The mean values of preoperative CRP in different tumor
subistes were compared using ANOVA. Chi-square test
with univariate analysis were used in this study. Survival
differences were compared with the log-rank test. SPSS
software, version 18.0 (SPSS, Chicago, IL, USA), was used
for data analysis. A two-sided p value ≤0.05 was defined as
statistically significant.
Ethics approval and consent to participate
All patients signed informed consent for participation of
this study. This study had ethics approval and consent by
the ethic committee in Chang Gung Memorial Hospital
(Institutional Review Board of Chang Gung Medical
Foundation, IRB No. 201600949B0), Taiwan, Republic of
China on August 24, 2016.
Results
Patient characteristics
The clinical information of 343 OSCC patients in this study
were shown in Table 1 (318 men and 25 women) and in
Additional file 1. Tongue (n = 132, 38.5%) and buccal
mucosa (n = 126, 36.7%) were the most common OSCC
sites in this study. Pathological tumor stage distributed as
stage I (n = 76, 22.2%), stage II (n = 66, 19.2%), stage III
(n = 43, 12.5%), stage IVa (n = 133, 38.8%), and stage
IVb (n = 25, 7.3%). The mean preoperative CRP was
6.96 mg/L (standard deviation (SD) ±12.06). The tumor
stages were not different between different tumor subsites
(p = 0.100). The mean CRP level was 5.90 mg/L (±SD
10.53), 8.37 mg/L (±SD 15.01), and 6.52 mg/L (±SD 8.90)
in tongue cancer, buccal cancer, and other oral cavity
Fig. 1 Patients with same tumor invasion into the skin. a Combined with peri-tumoral inflammation. b Without peri-tumoral inflammation
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cancers, respectively. The CRP levels were not signifi-
cantly different between subsites (ANOVA p = 0.240).
Association between CRP level with clinicopathologic
parameters and prognosis
The relationship between CRP levels and tumor clinico-
pathologic parameters in OSCCs were examined and
showed in Table 2. Advanced tumor status (p < 0.001),
tumor stage (p < 0.001), skin invasion (p < 0.001), bone in-
vasion (p < 0.001), and tumor depth ≥10 mm (p < 0.001)
and advanced pathologic nodal status (p = 0.006) and
lymphatic invasion (p = 0.068) were significantly corre-
lated with CRP elevation (CRP ≥ 5.0 mg/L).
We further analyzed the association between CRP and
clinicopathologic factors in different tumor sites (buccal,
tongue, and other locations). In buccal cancer (Table 3),
Table 1 Characteristics of 343 patients with OSCC
Characteristic Value
Age (year)





Site of primary cancer
Tongue 132 (38.5%)
Mouth floor 12 (3.5%)
Lip 24 (7.0%)
Buccal mucosa 126 (36.7%)
Alveolar ridge 31 (9.0%)
Hard palate 2 (0.6%)



















Table 2 Association between CRP and clinicopathologic
parameters (n = 343)
Characteristic CRP p value
Negative Positive
Pathologic tumor status
Early (T1–T2) (n = 210) 181 (86.2%) 29 (13.8%) <0.001
Advanced (T3–T4) (n = 133) 68 (51.1%) 65 (48.9%)
Pathologic N stage
N0 (n = 201) 156 (77.6%) 45 (22.4%) 0.006
N1 (n = 47) 36 (76.6%) 11 (23.4%) 0.002a
N2 (n = 94) 57 (60.6%) 37 (39.4%)
N3 (n = 1) 0 (0.0%) 1 (100.0%)
Nodal status
(−) metastasis, (−) ECS (n = 201) 156 (77.6%) 45 (22.4%) 0.006
(+) metastasis, (−) ECS (n = 59) 44 (74.6%) 15 (25.4%) 0.002a
(+) metastasis, (+) ECS (n = 83) 49 (59.0%) 34 (41.0%)
Differentiation
Well (n = 107) 77 (72.0%) 30 (28.0%) 0.308
Moderate (n = 192) 144 (75.0%) 48 (25.0%) 0.538a
Poor (n = 44) 28 (63.6%) 16 (36.4%)
Tumor stage
Early (I–II) (n = 142) 123 (86.6%) 19 (13.4%) <0.001
Advanced (III–IV) (n = 201) 126 (62.7%) 75 (37.3%)
Skin invasion
No (n = 304) 231 (76.0%) 73 (24.0%) <0.001
Yes (n = 39) 18 (46.2%) 21 (53.8%)
Nerve invasion
No (n = 229) 171 (74.7%) 58 (25.3%) 0.221
Yes (n = 114) 78 (68.4%) 36 (31.6%)
Blood vessel invasion
No (n = 331) 242 (73.1%) 89 (26.9%) 0.322b
Yes (n = 12) 7 (58.3%) 5 (41.7%)
Lymphatic invasion
No (n = 334) 245 (73.4%) 89 (26.6%) 0.068b
Yes (n = 9) 4 (44.4%) 5 (55.6%)
Tumor depth (≥10 mm)
No (n = 160) 137 (85.6%) 23 (14.4%) <0.001
Yes (n = 183) 112 (61.2%) 71 (38.8%)
Bone invasion
No (n = 275) 215 (78.2%) 60 (21.8%) <0.001
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CRP elevation (CRP ≥ 5.0 mg/L) was significantly associated
with advanced tumor status (p < 0.001), advanced
stage (p = 0.001), advanced pathological nodal status
(p = 0.009), nodal status with ECS (p = 0.003), tumor
depth ≥ 10 mm (p < 0.001), skin invasion (p < 0.001),
nerve invasion (p = 0.042), and bone invasion (p =
0.011).
In tongue cancer (Table 4), CRP elevation (CRP ≥
5.0 mg/L) showed a strong relationship with advanced
pathological tumor status (p < 0.001) and correlated with
advanced pathologic nodal status (p = 0.027) and ad-
vanced tumor stage (p = 0.021).
In other tumor subsites (Table 5), the CRP elevation
(CRP ≥ 5.0 mg/L) was significantly associated with ad-
vanced pathological tumor status (p = 0.001), tumor
stage (p = 0.009), and bone invasion (p < 0.001). It was
also correlated with tumor depth ≥10 mm (p = 0.009).
The association between CRP and survival
Comparing the prognosis between the two by univariate
analysis, the group with lower CRP (CRP < 5.0 mg/L)
has a longer disease-free survival (DFS) than the high
CRP group (CRP ≥ 5.0 mg/L), (log-rank test p ≤ 0.001,
Fig. 2a). Similarly, overall survival (OS) is longer in the
low CRP level group (CRP < 5.0 mg/L) compared to the
high CRP level group (CRP ≥ 5.0 mg/L) (log-rank test
p ≤ 0.001, Fig. 2b). The hazard ratio (HR) for CRP in-
cluding all subsites, DFS 1.902 (95% confidence interval
(CI) 1.302–2.778) and OS 2.235 (95% CI 1.393–3.585).
We analyzed the influence of CRP on survival according
to different subsites: the HR for CRP in tongue cancer
DFS 1.785 (95% CI 0.848–3.757); OS 1.535 (95% CI
0.630–3.741); the HR for CRP in buccal cancer, DFS
2.293 (95% CI 1.309–4.017); OS 3.610 (95% CI 1.732–
7.526); the HR for CRP in other cancer subsites, DFS
1.577 (95% CI 0.721–3.449), OS 1.252 (95% CI 0.403–
3.885).
Discussion
Our previous studies showed a positive relationship be-
tween CRP level elevation and advanced oral cavity cancer
stage [6]. Therefore, CRP has the potential to be a bio-
marker for oral cavity cancer and a predictor of prognosis
before treatment. In this study, we recruited more cases
(343 cases) to evaluate the connection between preopera-
tive serum CRP level, oral cavity cancer stage, and progno-
sis. In the present study, oral cavity cancer had a greater
prevalence between males, with mean age falling in the
middle age period. This distribution was probably due to
greater exposure to oral cavity cancer risk factors
(smoking, drinking, and chewing betel nut habit)
[14–17] in this subgroup. In contrary, the most com-
mon site of oral cavity cancer in the Western popula-
tion is the tongue. However, in Taiwan, due to betel
nut chewing, the common sites of oral cavity cancer
are buccal mucosa and tongue, compatible with our
patients’ tumor site distribution [18, 19].
Table 3 Association between CRP and clinicopathologic
parameters in buccal cancer (n = 126)
Characteristic CRP p value
Negative Positive
Pathologic tumor status
Early (T1–T2) (n = 71) 60 (84.5%) 11 (15.5%) <0.001
Advanced (T3–T4) (n = 55) 25 (45.5%) 30 (54.5%)
Pathologic N stage
N0 (n = 70) 52 (74.3%) 18 (25.7%) 0.009
N1 (n = 18) 15 (83.3%) 3 (16.7%) 0.006a
N2 (n = 37) 18 (48.6%) 19 (51.4%)
N3 (n = 1) 0 (0.0%) 1 (100.0%)
Nodal status
(−) metastasis, (−) ECS (n = 70) 52 (74.3%) 18 (25.7%) 0.003
(+) metastasis, (−) ECS (n = 27) 21 (77.8%) 6 (22.2%) 0.005a
(+) metastasis, (+) ECS (n = 29) 12 (41.4%) 17 (58.6%)
Differentiation
Well (n = 48) 28 (58.3%) 20 (41.7%) 0.211
Moderate (n = 62) 46 (74.2%) 16 (25.8%) 0.192a
Poor (n = 16) 11 (68.8%) 5 (31.2%)
Tumor stage
Early (I–II) (n = 48) 41 (85.4%) 7 (14.6%) 0.001
Advanced (III–IV) (n = 78) 44 (56.4%) 34 (43.6%)
Skin invasion
No (n = 96) 73 (76.0%) 23 (24.0%) <0.001
Yes (n = 30) 12 (40.0%) 18 (60.0%)
Nerve invasion
No (n = 86) 63 (73.3%) 23 (26.7%) 0.042
Yes (n = 40) 22 (55.0%) 18 (45.0%)
Blood vessel invasion
No (n = 122) 83 (68.0%) 39 (32.0%) 0.595b
Yes (n = 4) 2 (50.0%) 2 (50.0%)
Lymphatic invasion
No (n = 122) 84 (68.9%) 38 (31.1%) 0.101b
Yes (n = 4) 1 (25.0%) 3 (75.0%)
Tumor depth ≥10 mm
No (n = 60) 52 (86.7%) 8 (13.3%) <0.001
Yes (n = 66) 33 (50.0%) 33 (50.0%)
Bone invasion
No (n = 92) 68 (73.9%) 24 (26.1%) 0.011
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It is still a debate if the elevation of CRP could be due
to a concomitant pulmonary infection or other infection,
and be non-specific for oral cancer. In 18 of our cases,
the CRP levels were checked twice. The first test was at
the time of diagnosis, and the second test was performed
the day before surgery. Eighty-three percent of the pa-
tients had similar levels or a more elevated CRP level in
Table 4 Association between CRP and clinicopathologic
parameters in tongue cancer (n = 132)
Characteristic CRP p value
Negative Positive
Pathologic tumor status
Early (T1–T2) (n = 96) 83 (86.5%) 13 (13.5%) <0.001
Advanced (T3–T4) (n = 36) 19 (52.8%) 17 (47.2%)
Pathologic N stage
N0 (n = 77) 64 (83.1%) 13 (16.9%) 0.027
N1 (n = 15) 13 (86.7%) 2 (13.3%) 0.017a
N2 (n = 40) 25 (62.5%) 15 (37.5%)
Nodal status
(−) metastasis, (−) ECS (n = 77) 64 (83.1%) 13 (16.9%) 0.163
(+) metastasis, (−) ECS (n = 17) 12 (70.6%) 5 (29.4%) 0.066a
(+) metastasis, (+) ECS (n = 38) 26 (68.4%) 12 (31.6%)
Differentiation
Well (n = 33) 28 (84.8%) 5 (15.2%) 0.152
Moderate (n = 81) 63 (77.8%) 18 (22.2%)
Poor (n = 18) 11 (61.1%) 7 (38.9%)
Tumor stage
Early (I–II) (n = 64) 55 (85.9%) 9 (14.1%) 0.021
Advanced (III–IV) (n = 68) 47 (69.1%) 21 (30.9%)
Skin invasion
No (n = 131) 101 (77.1%) 30 (22.9%) 1.000
Yes (n = 1) 1 (100.0%) 0 (0.0%)
Nerve invasion
No (n = 77) 60 (77.9%) 17 (22.1%) 0.833
Yes (n = 55) 42 (76.4%) 13 (23.6%)
Blood vessel invasion
No (n = 130) 100 (76.9%) 30 (23.1%) 1.000b
Yes (n = 2) 2 (100.0%) 0 (0.0%)
Lymphatic invasion
No (n = 129) 101 (78.3%) 28 (21.7%) 0.129b
Yes (n = 3) 1 (33.3%) 2 (66.7%)
Tumor depth (≥10 mm)
No (n = 58) 49 (84.5%) 9 (15.5%) 0.080
Yes (n = 74) 53 (71.6%) 21 (28.4%)
Bone invasion
No (n = 129) 100 (77.5%) 29 (22.5%) 0.542b




Table 5 Association between CRP and clinicopathologic
parameters in subsites other than tongue and buccal mucosa
(n = 85)
Characteristic CRP p value
Negative Positive
Pathologic tumor status
Early (T1–T2) (n = 43) 38 (88.4%) 5 (11.6%) 0.001
Advanced (T3–T4) (n = 42) 24 (57.1%) 18 (42.9%)
Pathologic N stage
N0 (n = 54) 40 (74.1%) 14 (25.9%) 0.277
N1 (n = 14) 8 (57.1%) 6 (42.9%) 0.765a
N2 (n = 17) 14 (82.4%) 3 (17.6%)
Nodal status
(−) metastasis, (−) ECS (n = 54) 40 (74.1%) 14 (25.9%) 0.915
(+) metastasis, (−) ECS (n = 15) 11 (73.3%) 4 (26.7%) 0.694a
(+) metastasis, (+) ECS (n = 16) 11 (68.8%) 5 (31.2%)
Differentiation
Well (n = 26) 21 (80.8%) 5 (19.2%) 0.425
Moderate (n = 49) 35 (71.4%) 14 (28.6%) 0.195a
Poor (n = 10) 6 (60.0%) 4 (40.0%)
Tumor stage
Early (I–II) (n = 30) 27 (90.0%) 3 (10.0%) 0.009
Advanced (III–IV) (n = 55) 35 (63.6%) 20 (36.4%)
Skin invasion
No (n = 77) 57 (74.0%) 20 (26.0%) 0.677a
Yes (n = 8) 5 (62.5%) 3 (37.5%)
Nerve invasion
No (n = 66) 48 (72.7%) 18 (27.3%) 0.934
Yes (n = 19) 14 (73.7%) 5 (26.3%)
Blood vessel invasion
No (n = 79) 59 (74.7%) 20 (25.3%) 0.337a
Yes (n = 6) 3 (50.0%) 3 (50.0%)
Lymphatic invasion
No (n = 83) 60 (72.3%) 23 (27.7%) 0.383
Yes (n = 2) 2 (100.0%) 0 (0.0%)
Tumor depth ≥10 mm
No (n = 42) 36 (85.7%) 6 (14.3%) 0.009
Yes (n = 43) 26 (60.5%) 17 (39.5%)
Bone invasion
No (n = 54) 47 (87.0%) 7 (13.0%) <0.001
Yes (n = 31) 15 (48.4%) 16 (51.6%)
ECS extracapsular spread
aχ2 trend test
† Fisher’s exact test
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the second test; only three cases had lower CRP levels in
the second test (Fig. 3, paired t test p = 0.201). This indi-
cated that the serum CRP levels are stable in OSCC
cancer patients, and so, the serum level analyzed in our
study was not amenable to change in a different time
period.
CRP is an acute phase protein as the host reacts to an
inflammatory response and released from the liver into
the bloodstream. Because of its short plasma half-life and
robust reaction, it has been used clinically as a marker for
inflammatory or infectious status [10, 11, 20, 21]. Recently,
CRP has proved a predictive factor in certain human
cancers such as gastrointestinal, breast, lung, and gyneco-
logic cancers [9, 22–26]. There are three mechanisms
about the relationship between CRP elevation and cancer
prognosis: (1) oxidative damage caused by inflammation
promotes tumor growth, (2) the tumor growth and apop-
tosis induced the release of CRP, (3) inflammation is a
contributing factor to tumor progression and reflects in
the elevation of CRP. We demonstrated that the CRP level
was closely related with an increased squamous cell
carcinoma antigen (SCC-Ag) and neutrophil to
lymphocyte ratio (NLR) in peripheral blood tests at the
time of diagnosis in OSCC patients [7, 27]. The SCC-
Ag was closely related with primary tumor status and
lymph node metastasis, which could stand for the
tumor burden [7, 28, 29]. The elevated neutrophil ratio
could be from tumor growth and the consequent
immune response from the host. Circulating neutro-
phils contain and secrete various cytokines including
circulating matrix metalloproteinases [30], vascular
endothelial growth factor (VEGF) [31], platelet-derived
growth factor, fibroblast growth factor, CXCL8 [32],
elastases [33], and interleukin-8 [34]. These cytokines
create a microenvironment that facilitates extracellular
matrix remodeling, endothelial cell migration, and
tumor cell invasion. Also, the released cytokines such
as IL-6 could further stimulate the production of CRP
in the liver [8].
In this study, CRP elevation and tumor status presented
a clear positive correlation. To clarify the role of preopera-
tive serum CRP level in OSCC, we stratified our patients
into different subsites. There was a similar relationship
between CRP elevation and tumor status for each cancer
subsite. In the literature, nine studies investigated the roles
of CRP in OSCC (Table 6) [6, 35–40]. Only one study did
not find any association between CRP elevation and sur-
vival. Another point to consider is the fact that the
included studies used inconsistent cut-off values for CRP
levels, which caused heterogeneity in the influence of CPR
in prognosis. In a meta-analysis in urologic malignancies,
a similar condition of different cut-off points was ob-
served, and they found setting the level at 5.0 mg/L was
the most appropriate [41].
In this study, we found an elevated CRP was highly cor-
related with primary tumor status, tumor depth, and
Fig. 2 Survival curves in 343 OSCC patients related to the preoperative CRP level. a The lower CRP level group showed significantly better DFS
compared to the higher CRP group (p < 0.001). b The lower CRP level group showed significantly better OS compared to the higher CRP level
group (p < 0.001)
Fig. 3 The change of preoperative serum CRP levels in 18 OSCC
who had tests of CRP level twice before surgery
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lymph node metastasis in OSCCs. Regarding the tumor
subsites, the elevation of CRP in buccal cancer had the
most promising association with most clinicopathologic
factors. In addition, the elevation of CRP was related with
lymph node metastasis in buccal and tongue cancers,
while the association between increased CRP and ECS
was only found in buccal cancer (Tables 3, 4, and 5). The
stronger relationship between CRP and buccal cancer in
our series may be due the high incidence of AQ consump-
tion in our population, making the buccal mucosa the site
of greatest risk of contracting malignancy in betel quid
chewers [42, 43]. The intimate contact between the buccal
mucosa and the AQ during chewing induces chronic and
abnormal mucosa inflammation by promoting the release
of inflammatory mediators like IL-6, TNF-α, and PGE2 by
oral keratinocytes [44], playing a crucial role in the patho-
genesis of oral cancer.
We believe that there are limitations in this study. The
major one comes from the case number in each tumor
subsite. However, from this preliminary analysis, we be-
lieve that determining CRP levels preoperatively, espe-
cially in buccal cancer, would be relevant and useful to
clinicians because CRP measurement is rapid, inexpen-
sive, and repeatable in a clinical setting. Using CRP as a
biomarker could help clinicians select proper treatment
strategies for patients with OSCC, detecting which
patients would benefit from adjuvant treatment by pre-
dicting pathologically aggressive tumors based on their
CRP levels [6].
Conclusions
The presence of an elevated serum CRP level preopera-
tively (≥5.0 mg/L) is an important prognostic indicator
in oral cancer in the Taiwanese population. Elevated
CRP levels are associated with tumor stage and locore-
gional invasiveness. Furthermore, the prognostic predic-
tion is more evident in buccal cancer, which could be
attributed to the tumor’s behaviors related with AQ and
tobacco use.
Additional files
Additional file 1: Clinical information of 343 OSCC patients. (SAV 100 kb)
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Table 6 Literature review for the relationship of CRP level and survival in OSCC patients
Authors/year Tumor sites/nations Case no. Cut-off point, tumor stage Disease-free survival (DFS) Overall survival (OS)
Jablonska E. et al.
(1997) [5]
OSCC/Poland 42 Compares mean values, significant




et al. (2009) [36]
OSCC/United
Kingdom
60 CRP > 5.0 mg/L; significant with
tumor stage, p = 0.046
NA Significant in OS
(p < 0.001) (multivariate)
Kruse A.L. et al.
(2010) [37]
OSCC/Switzerland 278 CRP > 5.0 mg/L; NA No significant difference
(p = 0.137)
Not significant in time
to metastasis (p = 0.468)
Chen, H.H. et al.
(2011) [6]
OSCC/Taiwan 59 CRP≥ 5.0 mg/L, significant with
tumor stage, p = 0.005
Significant difference in 2-year
DFS, p < 0.001
Significant difference in
2-year OS, p = 0.013
Grimm, M. et al.
(2012) [45]
OSCC/Germany 187 CRP≥ 1.1 mg/L; LPI significantly
correlated with advanced tumor
stage, p = 0.0002a
5-year DFS, p < 0.0001 NA
Huang SF et al.
(2012) [7]
OSCC/Taiwan 142 CRP≥ 5.0 mg/L, significantly
related with tumor stage, p= 0.001
3-year DFS, p < 0.001 3-year OS, p = 0.008
Peter F. et al.
(2013) [38]
HNSCC/Germany 261 CRP≥ 2.0 mg/L, significant with
advanced tumor stage, p = 0.006;
nodal status, p = 0.045
NA 5-year OS, p < 0.0001




CRP≥ 5.0 mg/L, significant with
tumor stage, p < 0.001




et al. (2015) [40]
OSCC and soft palatal
ca/ United Kingdom
178 Modified Glasgow scale: combined
albumin (<35 g/L) and CRP
(>10 mg/L) level





survival (p < 0.001)
aCombines CRP, Hb, and WBC as laboratory prognostic index (LPI)
Tai et al. World Journal of Surgical Oncology  (2017) 15:47 Page 7 of 9
Availability of data and materials
All data generated or analyzed during this study are included in this
published article and its supplementary information files.
Authors’ contributions
SFT, HTC, CKY, and SFH conceived the idea for the manuscript, conducted a
literature search, and drafted the manuscript. SFH organized the manuscript
and critically revised the manuscript. SFT, CKT, AP, KHF, CTL, HMW, CJK, and
JTCC collected the data. HTC, CKY, and SFH analyzed the data. HTC plotted
the figures. CKT, AP, HMW, CKT, and JTCC critically revised the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent for the publication was obtained from the
participants for the images relating to participants in Fig. 1a, b.
Ethics approval and consent to participate
All patients signed informed consent for participation of this study. This
study had ethics approval and consent by the ethic committee in Chang
Gung Memorial Hospital (Institutional Review Board of Chang Gung Medical
Foundation, IRB No. 201600949B0), Taiwan, Republic of China.
Author details
1Department of Otolaryngology, Chang Gung Memorial Hospital, Linkou,
Taiwan. 2Chang Gung University, Taoyuan, Taiwan, Republic of China.
3Department of Public Health, Chang Gung University, Taoyuan, Taiwan,
Republic of China. 4Department of Otolaryngology, Chang Gung Memorial
Hospital, Keelung, Taiwan, Republic of China. 5Plastic and Reconstructive
Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan, Republic of China.
6Department of Radiation Oncology, Chang Gung Memorial Hospital, Chang
Gung University, Taoyuan, Taiwan, Republic of China. 7Department of
Medical Oncology, Chang Gung Memorial Hospital, Chang Gung University,
Taoyuan, Taiwan, Republic of China.
Received: 16 November 2016 Accepted: 1 February 2017
References
1. Bjorkqvist AM, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Tammilehto L,
Mattson K, Vainio H, Knuutila S. DNA gains in 3q occur frequently in
squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes
Chromosomes Cancer. 1998;22:79–82.
2. Wen CP, Tsai SP, Cheng TY, Chen CJ, Levy DT, Yang HJ, Eriksen MP.
Uncovering the relation between betel quid chewing and cigarette
smoking in Taiwan. Tob Control. 2005;14:16–22.
3. Bran B, Bran G, Hormann K, Riedel F. The platelet-derived growth factor
receptor as a target for vascular endothelial growth factor-mediated anti-
angiogenetic therapy in head and neck cancer. Int J Oncol. 2009;34:255–61.
4. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S,
Kritchevsky SB. Circulating levels of inflammatory markers and cancer risk in
the health aging and body composition cohort. Cancer Epidemiol
Biomarkers Prev. 2005;14:2413–8.
5. Jablonska E, Piotrowski L, Grabowska Z. Serum levels of IL-1b, IL-6, TNF-
a, sTNF-RI and CRP in patients with oral cavity cancer. Pathol Oncol
Res. 1997;3:126–9.
6. Chen HH, Chen IH, Liao CT, Wei FC, Lee LY, Huang SF. Preoperative
circulating C-reactive protein levels predict pathological aggressiveness in
oral squamous cell carcinoma: a retrospective clinical study. Clin
Otolaryngol. 2011;36:147–53.
7. Huang SF, Wei FC, Liao CT, Wang HM, Lin CY, Lo S, Huang JJ, Chen IH, Kang
CJ, Chien HT, Chen HH. Risk stratification in oral cavity squamous cell
carcinoma by preoperative CRP and SCC antigen levels. Ann Surg Oncol.
2012;19:3856–64.
8. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest.
2003;111:1805–12.
9. Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-reactive
protein is an important biomarker for prognosis tumor recurrence and
treatment response in adult solid tumors: a systematic review. PLoS
One. 2015;10:e0143080.
10. Coventry BJ, Ashdown ML, Quinn MA, Markovic SN, Yatomi-Clarke SL,
Robinson AP. CRP identifies homeostatic immune oscillations in cancer
patients: a potential treatment targeting tool? J Transl Med. 2009;7:102.
11. Van Hemelrijck M, Holmberg L, Garmo H, Hammar N, Walldius G, Binda E,
Lambe M, Jungner I. Association between levels of C-reactive protein and
leukocytes and cancer: three repeated measurements in the Swedish
AMORIS study. Cancer Epidemiol Biomarkers Prev. 2011;20:428–37.
12. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer
staging manual. American Cancer Society. New York: Springer; 2010.
13. Hsu YP, Hsieh CH, Chien HT, Lai CH, Tsao CK, Liao CT, Kang CJ, Wang HM,
Chang JT, Huang SF. Serum markers of CYFRA 21–1 and C-reactive proteins
in oral squamous cell carcinoma. World J Surg Oncol. 2015;13:253.
14. Goldstein BY, Chang SC, Hashibe M, La Vecchia C, Zhang ZF. Alcohol
consumption and cancers of the oral cavity and pharynx from 1988 to
2009: an update. Eur J Cancer Prev. 2010;19:431–65.
15. Radoi L, Menvielle G, Cyr D, Lapotre-Ledoux B, Stucker I, Luce D, Group IS.
Population attributable risks of oral cavity cancer to behavioral and medical
risk factors in France: results of a large population-based case-control study,
the ICARE study. BMC Cancer. 2015;15:827.
16. Sharan RN, Mehrotra R, Choudhury Y, Asotra K. Association of betel nut with
carcinogenesis: revisit with a clinical perspective. PLoS One. 2012;7:e42759.
17. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado
MP, Dal Maso L, Daudt AW, Fabianova E, Fernandez L, Wunsch-Filho V,
Franceschi S, Hayes RB, Herrero R, Kelsey K, Koifman S, La Vecchia C, Lazarus
P, Levi F, Lence JJ, Mates D, Matos E, Menezes A, McClean MD, Muscat J,
Eluf-Neto J, Olshan AF, Purdue M, Rudnai P, Schwartz SM, Smith E, Sturgis
EM, Szeszenia-Dabrowska N, Talamini R, Wei Q, Winn DM, Shangina O,
Pilarska A, Zhang ZF, Ferro G, Berthiller J, Boffetta P. Interaction between
tobacco and alcohol use and the risk of head and neck cancer: pooled
analysis in the International Head and Neck Cancer Epidemiology
Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:541–50.
18. Scully C, Bedi R. Ethnicity and oral cancer. Lancet Oncol. 2000;1:37–42.
19. Ko YC, Chiang TA, Chang SJ, Hsieh SF. Prevalence of betel quid chewing
habit in Taiwan and related sociodemographic factors. J Oral Pathol Med.
1992;21:261–4.
20. Lee S, Choe JW, Kim HK, Sung J. High-sensitivity C-reactive protein and
cancer. J Epidemiol. 2011;21:161–8.
21. Ehrsson YT, Hellstrom PM, Brismar K, Sharp L, Langius-Eklof A, Laurell G.
Explorative study on the predictive value of systematic inflammatory and
metabolic markers on weight loss in head and neck cancer patients
undergoing radiotherapy. Support Care Cancer. 2010;18:1385–91.
22. Asegaonkar SB, Asegaonkar BN, Takalkar UV, Advani S, Thorat AP. C-reactive
protein and breast cancer: new insights from old molecule. Int J Breast
Cancer. 2015;2015:145647.
23. Steffens S, Al Ghazal A, Steinestel J, Lehmann R, Wegener G, Schnoeller TJ,
Cronauer MV, Jentzmik F, Schrader M, Kuczyk MA, Schrader AJ. High CRP
values predict poor survival in patients with penile cancer. BMC Cancer.
2013;13:223.
24. Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G,
Schrader M, Kuczyk MA, Schrader AJ. Validation of CRP as prognostic marker
for renal cell carcinoma in a large series of patients. BMC Cancer. 2012;12:399.
25. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL,
Bowman ED, Engels EA, Caporaso NE, Harris CC. Increased levels of
circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung
cancer. J Natl Cancer Inst. 2011;103:1112–22.
26. Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR,
Chanock SJ, Goedert JJ, Engels EA. C-reactive protein and risk of lung
cancer. J Clin Oncol. 2010;28:2719–26.
27. Fang HY, Huang XY, Chien HT, Chang JT, Liao CT, Huang JJ, Wei FC, Wang
HM, Chen IH, Kang CJ, Huang SF. Refining the role of preoperative C-
reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell
carcinoma. Laryngoscope. 2013;123:2690–9.
28. Adel M, Tsao CK, Wei FC, Chien HT, Lai CH, Liao CT, Wang HM, Fan KH, Kang
CJ, Chang JT, Huang SF. Preoperative SCC antigen, CRP serum levels, and
lymph node density in oral squamous cell carcinoma. Medicine (Baltimore).
2016;95:e3149.
29. Lin WH, Chen IH, Wei FC, Huang JJ, Kang CJ, Hsieh LL, Wang HM, Huang SF.
Clinical significance of preoperative squamous cell carcinoma antigen in
oral-cavity squamous cell carcinoma. Laryngoscope. 2011;121:971–7.
Tai et al. World Journal of Surgical Oncology  (2017) 15:47 Page 8 of 9
30. Shamamian P, Schwartz JD, Pocock BJ, Monea S, Whiting D, Marcus SG,
Mignatti P. Activation of progelatinase A (MMP-2) by neutrophil elastase,
cathepsin G, and proteinase-3: a role for inflammatory cells in tumor
invasion and angiogenesis. J Cell Physiol. 2001;189:197–206.
31. Di Carlo E, Forni G, Musiani P. Neutrophils in the antitumoral immune
response. Chem Immunol Allergy. 2003;83:182–203.
32. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related
inflammation, the seventh hallmark of cancer: links to genetic instability.
Carcinogenesis. 2009;30:1073–81.
33. Scapini P, Nesi L, Morini M, Tanghetti E, Belleri M, Noonan D, Presta M,
Albini A, Cassatella MA. Generation of biologically active angiostatin kringle
1–3 by activated human neutrophils. J Immunol. 2002;168:5798–804.
34. De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in
promoting the metastatic phenotype of tumors releasing interleukin-8. Clin
Cancer Res. 2004;10:4895–900.
35. Jablonska E, Puzewska W, Grabowska Z, Jablonski J, Talarek L. VEGF, IL-18
and NO production by neutrophils and their serum levels in patients with
oral cavity cancer. Cytokine. 2005;30:93–9.
36. Khandavilli SD, Ceallaigh PÓ, Lloyd CJ, Whitaker R. Serum C-reactive protein
as a prognostic indicator in patients with oral squamous cell carcinoma.
Oral Oncol. 2009;45:912–4.
37. Kruse AL, Luebbers HT, Gratz KW. C-reactive protein levels: a prognostic marker
for patients with head and neck cancer? Head Neck Oncol. 2010;2:21.
38. Peter F, Wittekindt C, Finkensieper M, Kiehntopf M, Guntinas-Lichius O.
Prognostic impact of pretherapeutic laboratory values in head and neck
cancer patients. J Cancer Res Clin Oncol. 2013;139:171–8.
39. Chen IH, Liao CT, Wang HM, Huang JJ, Kang CJ, Huang SF. Using SCC
antigen and CRP levels as prognostic biomarkers in recurrent oral cavity
squamous cell carcinoma. PLoS One. 2014;9:e103265.
40. Farhan-Alanie OM, McMahon J, McMillan DC. Systemic inflammatory
response and survival in patients undergoing curative resection of oral
squamous cell carcinoma. Br J Oral Maxillofac Surg. 2015;53:126–31.
41. Luo Y, Fu SJ, She DL, Xiong HU, Yang LI. Preoperative C-reactive protein as
a prognostic predictor for upper tract urothelial carcinoma: a systematic
review and meta-analysis. Mol Clin Oncol. 2015;3:924–8.
42. Lee JJ, Kok SH, Kuo YS, Yang PJ, Hahn LJ. Carcinoma of buccal mucosa—a
representative betel nut oral cancer. Formosan J Med. 1997;1:638–47.
43. Chen YK, Huang HC, Lin LM, Lin CC. Primary oral squamous cell carcinoma:
an analysis of 703 cases in southern Taiwan. Oral Oncol. 1999;35:173–9.
44. Jeng JH, Wang YJ, Chiang BL, Lee PH, Chan CP, Ho YS, Wang TM, Lee JJ,
Hahn LJ, Chang MC. Roles of keratinocyte inflammation in oral cancer:
regulating the prostaglandin E2, interleukin-6 and TNF-alpha production of
oral epithelial cells by areca nut extract and arecoline. Carcinogenesis.
2003;24:1301–15.
45. Grimm M, Lazariotou M: Clinical relevance of a new pre-treatment
laboratory prognostic index in patients with oral squamous cell carcinoma.
Med Oncol 2012, 29: 1435-1447.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Tai et al. World Journal of Surgical Oncology  (2017) 15:47 Page 9 of 9
